Sarah Cannon

What Sarah Cannon does

Sarah Cannon is the Cancer Institute of HCA Healthcare, operating as a wholly-owned subsidiary that delivers integrated oncology services through a network of affiliated hospitals and physician practices spanning 20 US states and the United Kingdom. Founded in 1993 in Nashville, Tennessee as the first community-based cancer research program, the network treats 130,000+ new cancer patients annually, performs 1,600+ transplants and cellular therapies (making it the largest provider of cellular therapy in the United States), delivers 900+ daily radiation treatments, and enrolls 4,500+ patients per year on clinical trials including 750+ first-in-human studies. Service offerings include multidisciplinary tumor-board-driven care, specialized nurse navigation, transplant and cellular therapy, radiation oncology, and a clinical research arm under the Sarah Cannon Research Institute (SCRI), which was expanded in 2022 via a joint venture with the former US Oncology Research into a 250-location, 24-state research network.

The core technology platform combines physician-led multidisciplinary governance, the latest imaging and profiling technology, customized data informatics systems for quality measurement, and disease-specific nurse navigation. Sarah Cannon acquired Genospace in January 2017 to add molecular profiling and patient-matching capabilities for clinical trial enrollment and personalized treatment. The network holds 70+ Commission on Cancer, 30+ NAPBC, 9 FACT, and 21 ACR accreditations. In 2024, HCA Healthcare rebranded and unified its cancer care offering as the Sarah Cannon Cancer Network, consolidating hospital partnerships under a single identity.

The business model is healthcare services delivery: revenue is generated through patient treatment services (diagnostics, chemotherapy, radiation therapy, transplants, cellular therapies) at HCA Healthcare hospitals and partner facilities, supplemented by pharma-sponsored clinical trial revenue. As a wholly-owned subsidiary, Sarah Cannon does not disclose stand-alone revenue; financial results are consolidated within HCA Healthcare's hospital operations segment. The go-to-market is enterprise-style within the HCA hospital network, with additional patient acquisition supported by the askSARAH virtual cancer navigation service and HCA Healthcare's broader marketing infrastructure across social, content, and earned media channels.

Name

Sarah Cannon

Legal name

Sarah Cannon

Website

https://sarahcannon.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Sarah Cannon, the Cancer Institute of HCA Healthcare, provides integrated community-based cancer care — including diagnostics, radiation, cellular therapy, and clinical trials — across 20 US states and the United Kingdom, treating 130,000+ new patients annually.

Ownership category

akta.pro rank

Product category

Oncology / Cancer Care Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (6223), Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Health Care and Social Assistance (62)

SIC

Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-General Medical & Surgical Hospitals, Nec (8062)

akta.pro primary industry

Medical Oncology (HLAKAFAB)

akta.pro secondary industries

Oncology & Cancer Specialty Hospitals (HLAFAHAC), Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM), Oncology Remote Symptom Monitoring & Care Navigation (HLALAFAD), Oncology Telemedicine Platforms (HLALAGAH)

Keywords

• Cancer care services
• Oncology treatment
• Clinical trials
• Cellular therapy
• Radiation oncology

Headquarters

HQ city

Nashville

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Healthcare Services Delivery: Sarah Cannon generates revenue through providing cancer care services at affiliated HCA Healthcare hospitals and partner facilities. Revenue is derived from patient treatment services including diagnostics, chemotherapy, radiation therapy, transplants, cellular therapies, and clinical trial participation.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Sarah Cannon delivers integrated cancer care services through the HCA Healthcare Sarah Cannon Cancer Network, a network of partnering hospitals and physician practices across 20 US states and the United Kingdom. The core offering includes cancer screening, diagnosis, treatment (medical, surgical, radiation oncology, transplant, and cellular therapy), clinical trial access via the Sarah Cannon Research Institute (SCRI), and survivorship support through a specialized Nurse Navigation Program.

Product overview

Sarah Cannon operates as a network-based cancer care platform under HCA Healthcare, comprising the Sarah Cannon Cancer Network, the Sarah Cannon Research Institute (SCRI), and integrated service offerings including nurse navigation, transplant and cellular therapy, and radiation oncology. The network provides comprehensive cancer care from screening and diagnosis through treatment and survivorship across 20+ states and the UK, treating 130,000+ new cancer patients annually and conducting 4,500+ clinical trial enrollments per year.

Differentiator

Problem solved

Functional benefit

Brands

• Sarah Cannon Research Institute (SCRI): One of the largest patient-centric clinical trial organizations in the world, conducting drug development at every phase including first-in-human studies

Products and services

• HCA Healthcare Sarah Cannon Cancer Network A unified network of cancer care hospitals and centers across the United States and United Kingdom, offering world-class cancer care close to home through physician leadership, cutting-edge technology, and specialized nurse navigation. The network comprises partnering hospitals providing care from screening and diagnosis through treatment and survivorship.
• Sarah Cannon Research Institute (SCRI) One of the largest patient-centric clinical trial organizations in the world, conducting drug development at every phase including first-in-human studies. Brings together physicians accruing patients to clinical trials at more than 250 locations in 24 states.
• Nurse Navigation Program A specialized nurse navigation service ensuring patients and their team of physicians have a constant point of contact throughout the cancer journey. Sarah Cannon Nurse Navigators are required to have special training in specific cancer types to help patients understand their unique cancer, assist in removing barriers, and offer emotional support.
• Transplant and Cellular Therapy Comprehensive transplant and cellular therapy services, with Sarah Cannon being the largest provider of cellular therapy in the United States, performing 1,600+ annual transplants and cellular therapies across 9 FACT-accredited programs.
• Radiation Oncology Radiation oncology treatment services provided through Sarah Cannon's radiation oncology centers, delivering 900+ daily radiation treatments in the United States.

Quantifiable outcome

• 130,000+ new cancer patients treated annually
• +5 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• US Oncology Research (former)coreStrategic or Co-development Partner · 1 January 2022In 2022, Sarah Cannon Research Institute (SCRI) formed a joint venture with former US Oncology Research to enhance clinical trial access and availability across the country. The combined research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 24 states. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• US Oncology Network (McKesson): Nation's largest network of community-based oncology practices, backed by McKesson. The former US Oncology Research entity joined SCRI's JV in 2022, making McKesson a direct comparator in community oncology trials and practice services.
• OneOncology: PE-backed platform partnering with independent community oncology practices to scale operations, payer contracting, and clinical research. Closely comparable to Sarah Cannon in physician-led community oncology and trial-enabled care delivery.
• Tennessee Oncology: Large independent community oncology practice based in Sarah Cannon's home state of Tennessee, with its own clinical trial program (Sarah Cannon Research Institute was historically spun out of this ecosystem). Closely comparable in community oncology and trials.
• Florida Cancer Specialists & Research Institute: Large physician-owned community oncology practice operating across Florida with extensive clinical trial and cellular therapy programs. Comparable to Sarah Cannon in community oncology scale, trial activity, and value-based care focus.
• The Oncology Institute: Public, community-based oncology platform providing medical oncology, infusion, and clinical trials across multiple states. Directly competes with Sarah Cannon for community oncology patients and trial enrollment outside academic centers.

Broad incumbents

• Memorial Sloan Kettering Cancer Center: Elite NCI-designated cancer center with industry-leading clinical trials, precision oncology, and cellular therapy. A core benchmark for trial sophistication that community oncology networks must complement rather than replace.
• City of Hope: NCI-designated comprehensive cancer center with extensive clinical trials, cellular therapy, and a national care delivery network. Comparable to Sarah Cannon in cellular therapy leadership and trial volume but with academic and prestige advantages.
• MD Anderson Cancer Center: The leading U.S. academic cancer center and benchmark for cancer treatment, research, and trials. Represents the prestige ceiling that community networks like Sarah Cannon are differentiated against rather than competing head-on.
• GenesisCare: Global private oncology and cardiology provider with significant U.S. radiation oncology footprint. Comparable to Sarah Cannon in scaled community oncology service delivery and PE-backed growth orientation.

Regional players

• Huntsman Cancer Institute: NCI-designated comprehensive cancer center based at the University of Utah with regional dominance across the Mountain West. Comparable in trial activity and accreditation profile to a regional Sarah Cannon hub.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/hcahealthcare
• Facebookfacebook.com/SarahCannonCancerNetwork
• LinkedInlinkedin.com/company/sarah-cannon
• Instagraminstagram.com/hcahealthcare
• Xx.com/sarahcannonpr

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sarah Cannon